Back

Prevalence of clinically actionable hsCRP and implications for statin eligibility and residual ASCVD risk in the United States

30 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Novel markers to prevent cardiovascular risk Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Nicholas Chiu

Mass General Brigham, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Gene-exposure interactions regulate cytokine-mediated chronic inflammation and cardiac remodeling
Doctor M. Coriano' (London, GB)
Abstract Slides
Presentation thumbnail
Longitudinal hsCRP assessment in routine care refines residual inflammatory risk estimates
Professor D. Wolf (Freiburg, DE)
Abstract Slides
Presentation thumbnail
Proposition of reference tables for a novel hs-cTnT assay to define “normal” considering relevant determinants in the general population
Doctor J. Lehmacher (Hamburg, DE) Professor R. Twerenbold (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Prognostic utility of a next-generation high-sensitivity cardiac troponin T assay compared to an established high-sensitivity cardiac troponin I assay in the general population
Professor R. Twerenbold (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Treatment-adjusted detection and outcome risk for familial hypercholesterolaemia: dual external validation in 4,028 genetically confirmed cases across specialist and UKbiobank settings
Doctor N. Genedy (Cardiff, GB)

Access the full session

Session thumbnail
Novel markers to prevent cardiovascular risk
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
The real-life prevalence and risk factors of elevated CRP in patients from cardiology outpatient clinics. The results from the STAR-Lp(a) study.
1 September 2025
thumbnail
Congress Presentation
Residual inflammatory risk.
29 August 2022
thumbnail
Congress Presentation
A 4-protein biomarker risk score enhances cardiovascular risk assessment: insights from the multi-ethnic study of atherosclerosis
30 August 2025
thumbnail
Congress Presentation
Distribution and clinical correlates of elevated NT-proBNP among U.S. adults
21 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources